Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT02967692
Title	A Study of the Anti-PD1 Antibody PDR001, in Combination With Dabrafenib and Trametinib in Advanced Melanoma (COMBI-i)
Recruitment	Active, not recruiting
Gender	both
Phase	Phase III
Variant Requirements	Yes
Sponsors	Novartis Pharmaceuticals
Indications	melanoma
Therapies	Dabrafenib + Spartalizumab + Trametinib Dabrafenib + Trametinib
Age Groups:	adult \| senior
Covered Countries	USA \| ITA \| GBR \| FRA \| ESP \| DEU \| CAN \| BEL \| AUT \| AUS